Eli Lilly reported strong earnings for the second quarter, beating on the top and bottom lines. Disappointing trial results ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The economic and market risk is that the “data-dependent” Fed is relying on faulty data. Thus, they may wait too long to cut rates, or not cut them enough to stave off a recession. To wit, they waited ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump's tariffs taking effect on dozens of countries ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.